EULAV Asset Management’s Exact Sciences EXAS Stock Holding History

EULAV Asset Management’s Portfolio EXAS Stock Details EXAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-266,000	Closed	-$14.6M	–	150
2025 Q3	$14.6M	Sell	266,000 -17,000	-6%	-$849K	0.34%	82
2025 Q2	$15M	Sell	283,000 -52,000	-16%	-$2.64M	0.35%	75
2025 Q1	$14.5M	Buy	335,000 +50,000	+18%	+$2.53M	0.36%	73
2024 Q4	$16M	Sell	285,000 -20,000	-7%	-$1.24M	0.39%	69
2024 Q3	$20.8M	Buy	305,000 +20,000	+7%	+$1.13M	0.51%	57
2024 Q2	$12M	Sell	285,000 -33,000	-10%	-$1.82M	0.33%	80
2024 Q1	$22M	Buy	318,000 +61,000	+24%	+$3.86M	0.6%	50
2023 Q4	$19M	Buy	257,000 +18,000	+8%	+$1.18M	0.59%	53
2023 Q3	$16.3M	Buy	239,000 +14,000	+6%	+$1.19M	0.6%	55
2023 Q2	$21.1M	Sell	225,000 -5,000	-2%	-$390K	0.79%	44
2023 Q1	$15.6M	Sell	230,000 -25,000	-10%	-$1.61M	0.61%	51
2022 Q4	$12.6M	Sell	255,000 -20,000	-7%	-$817K	0.54%	57
2022 Q3	$8.94M	Sell	275,000 -10,000	-4%	-$412K	0.4%	73
2022 Q2	$11.2M	Sell	285,000 -19,000	-6%	-$1.02M	0.46%	66
2022 Q1	$21.3M	Sell	304,000 -76,000	-20%	-$5.56M	0.63%	56
2021 Q4	$29.6M	Buy	380,000 +55,000	+17%	+$4.85M	0.75%	47
2021 Q3	$31M	Buy	325,000 +120,000	+59%	+$12.7M	0.82%	43
2021 Q2	$25.5M	Buy	205,000 +7,000	+4%	+$835K	0.67%	55
2021 Q1	$26.1M	Sell	198,000 -20,000	-9%	-$2.74M	0.7%	50
2020 Q4	$28.9M	Sell	218,000 -25,000	-10%	-$3.02M	0.76%	40
2020 Q3	$24.8M	Buy	243,000 +49,000	+25%	+$4.23M	0.73%	42
2020 Q2	$16.9M	Sell	194,000 -42,501	-18%	-$3.4M	0.55%	60
2020 Q1	$13.7M	Buy	236,501 +55,000	+30%	+$4.47M	0.55%	63
2019 Q4	$16.8M	Buy	181,501 +28,000	+18%	+$2.46M	0.58%	61
2019 Q3	$13.9M	Sell	153,501 -31,499	-17%	-$3.59M	0.51%	61
2019 Q2	$21.8M	Sell	185,000 -12,000	-6%	-$1.21M	0.82%	34
2019 Q1	$17.8M	Sell	197,000 -22,000	-10%	-$1.87M	0.73%	46
2018 Q4	$13.8M	Buy	219,000 +19,000	+10%	+$1.3M	0.69%	47
2018 Q3	$15.8M	Sell	200,000 -30,000	-13%	-$1.96M	0.68%	46
2018 Q2	$13.8M	Buy	230,000 +24,000	+12%	+$1.29M	0.63%	51
2018 Q1	$8.31M	Buy	206,000 +31,000	+18%	+$1.51M	0.4%	83
2017 Q4	$9.19M	Sell	175,000 -40,000	-19%	-$2.14M	0.43%	77
2017 Q3	$10.1M	Sell	215,000 -2,000	-0.9%	-$80.5K	0.48%	65
2017 Q2	$7.67M	Buy	+217,000	New	+$6.7M	0.38%	91

Other funds holding EXAS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

EULAV Asset Management's EXAS Position: Q4 2025 in Review

EULAV Asset Management sold out of Exact Sciences (EXAS) in Q4 2025, closing a stake of 266,000 shares — an estimated $14.6M sold.

EULAV Asset Management first reported a position in EXAS in Q2 2017 and held it in 34 quarters. The position peaked at $31M in Q3 2021. 711 funds tracked by Wall St. Rank hold EXAS as of Q4 2025.

EULAV Asset Management reported no remaining Exact Sciences position as of Q4 2025 after selling out during the quarter.
EULAV Asset Management sold 266,000 Exact Sciences shares in Q4 2025, an estimated $14.6M.
EULAV Asset Management first reported a position in Exact Sciences in Q2 2017 and held it in 34 quarters.
EULAV Asset Management's Exact Sciences position peaked at $31M in Q3 2021.
711 funds tracked by Wall St. Rank held Exact Sciences as of Q4 2025.

Based on EULAV Asset Management's 13F filing for Q4 2025, filed 11 Feb 2026.